Now Is A Suitable Moment For A Long-Term Purchase Of DENTSPLY Sirona Inc (NASDAQ: XRAY)

#####

Currently, there are 199.30M common shares owned by the public and among those 197.98M shares have been available to trade.

#####

#####

#####

The company’s stock has a 5-day price change of 3.08% and 28.00% over the past three months. XRAY shares are trading -37.86% year to date (YTD), with the 12-month market performance down to -13.54% lower. It has a 12-month low price of $12.16 and touched a high of $27.95 over the same period. XRAY has an average intraday trading volume of 2.63 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.82%, 2.03%, and -7.82% respectively.

Institutional ownership of DENTSPLY Sirona Inc (NASDAQ: XRAY) shares accounts for 103.21% of the company’s 199.30M shares outstanding.

It has a market capitalization of $3.27B and a beta (3y monthly) value of 0.96. The earnings-per-share (ttm) stands at -$4.54. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.70% over the week and 3.19% over the month.

Analysts forecast that DENTSPLY Sirona Inc (XRAY) will achieve an EPS of 0.5 for the current quarter, 0.46 for the next quarter and 2.05 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.49 while analysts give the company a high EPS estimate of 0.49. Comparatively, EPS for the current quarter was 0.49 a year ago. Earnings per share for the fiscal year are expected to increase by 13.53%, and 8.00% over the next financial year.

#####

Looking at the support for the XRAY, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on April 15, 2025, with the firm’s price target at $14. Wells Fargo was of a view on February 14, 2025 that the stock is Equal Weight, while Jefferies gave the stock Hold rating on January 23, 2025, issuing a price target of $30- $20. Evercore ISI on their part issued In-line rating on January 07, 2025.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.